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Classification of Positive Inotropic Agents
ARTHUR M. FELDMAN, MD, PHD, FACC
Baltimore, Maryland
Although there is Increasing recognition that all inotropic agents
are not alike, they continue to be viewed in the generic sense
because of the lack of a classification system. Analogous to the
classification system proposed for the antiarrhythmic agents over
20 years ago, a classification system is proposed that categorizes
inotropic agents according to their mechanisms of action. Agents
are classified as those that augment contractility by increasing
intracellular levels of cyclic adenosine monophosphate (class 1);
affect Ion channels or pumps (class 11); modulate intracellular
The initiating event in the development of clinical congestive
heart failure is myocardial injury with a resulting decrease in
cardiac output and an increase in left ventricular filling
pressures. However, the role of positive inotropic agents or
drugs that enhance pump function in the management of
patients with congestive heart failure has been controversial
(1-3) . Theoretic arguments have been raised that both sup-
port and reject the use of inotropic agents in patients with
heart failure . Intuitively, it appears that inotropic agents
could be beneficial by supporting pump function and in so
doing decreasing both adrenergic drive (4) as well as renin-
angiotensin activation (5) . In contrast, investigators have
suggested that in patients with heart failure, inotropic agents
may be deleterious because they can be arrhythmogenic, can
have adverse effects on myocardial energetics, can poten-
tially impair cardiac relaxation and may accelerate the
progression of disease (6-8) . However, one factor that has
contributed to the confusion regarding the role of therapy
with isotropic agents in the management of patients with
congestive failure is that these agents have been considered
in the generic sense . It has become increasingly clear that all
inotropic agents are not alike; therefore, the purpose of this
review is to propose a classification of inotropic agents based
on their mechanisms of action (Table 1) .
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calcium regulation (class III), and augment contractility through
multiple pathways (class IV) . This classification system does not
suggest that some classes of isotropic agents might be more
effective than others nor does it imply that potential beneficial
effects are shared by all members of each class of drugs. However,
It provides a framework for better urderstar - 'ag of the potential
benefits and limitations of the traditional inotiopic agents as well
as the increasing number of new investigational drugs .
(J Ass Coil Cardiol 1993
;22:1223-7)
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Class I: Inotropic Agents That
Increase Intracellular Cyclic
Adenosine Monophosphate
Both the beta-adrenergic receptor agonists and the phos-
phodiesterase inhibitors increase cardiac contractility by
increasing intracellular levels of the second messenger cyclic
adenosine monophosphate (AMP) (9,10) . Stimulation of the
beta-adrenergic receptor results in activation of the stimula-
tory guanine nucleotide-binding regulatory protein (aG q) and
stimulation of the effector enzyme adenylyl cyclase resulting
in enhanced production of cyclic AMP (Fig . 1). Once syn.,
thesized, cyclic AMP activates a cyclic AMP-dependent
protein kinase with subsequent phosphorylation c4a group
of myocardial proteins leading to both improved contraction
and relaxation . Cyclic AMP is metabolized to an inactive
by-product by the enzyme phosphodiesterase . In the pres-
ence of adequate quantities of intracellular cyclic AMP,
inhibition of phosphodiesterase can also result in increased
intracellular cyclic AMP levels and enhanced contractility
and relaxation .
Intuitively, one would suspect that activation of the
adrenergic pathway would provide inotropic support . Al-
though a substantial number of oral adrenergic agonists have
been evaluated in the management of congestive heart
failure, none have proved consistently efficacious with long-
term use (11,12). Indeed, a multicenter trial assessing the
efficacy of the long-term administration of the partial beta-
adrenergic agonist x.amoterol demonstrated a substantial
increase in mortality in the xamoterol-treated patients (13) .
It is unclear why the oral beta-adrenergic agonists fail to
benefit patients with congestive failure; however, several
hypotheses have been proposed : 1) desensitization of the
beta-adrenergic pathway, 2) arrhythmogenic effects of cyclic
AMP, and 3) direct cardiotoxic effects of cyclic AMP (14).
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TiMe 1. Classes of Inotropic Agents by Mechanism of Action
Class
Dc&Wou
I
Agents that increase intracellular cyclic adenosine
monophosphate
Beta-adrenergic egonists
Phosphodiesterase inhibitors
II
Agents that affect sarcolemmal ions
pumps/channels
Dtpxk
11
Agents that modulate intracellular calcium mechanisms by either :
A) Release of sucoplasmic reticulum calcium (1P
3) or
B) Increased sensitization of the eonduttile proteins to calcium
IV Ikup having multiple mechanisms of action
Pimobendan
Veanarinone
1Pr inoaltol triphosphate .
A group of oral phosphodiesterase Wiibitors have also
undergone clinical investigation in the United States during
the past decade. These have included milrinone, enoximone
and imazodan . The long-team use of these phosphodiester-
ase inhibitors was not associated with improved exercise
performance (15-17) . Of greater concern was the finding of a
trend toward increased mortality in those patients receiving
phosphodiesterase inhibitors (15,16) . Indeed, those patients
receiving milrinone in the large PROMISE trial (18) had a
28% increased mortality over that of patients receiving
placebo. Therefore, enthusiasm for oral agents that augment
contractility predominantly by increasing intracellular levels
of cyclic AMP has diminished .
Although oral inotropia: agents that increase intracellular
cyclic AMP have not proved beneficial, intravenous adren-
ergic agonists have become a standard of therapy in the
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short-term management of patients with congestive heart
failure. First introduced in 1975, dobutamine is a beta-
adrenergic agonist that provides sustained inotropic support
inpatients with severe congestive failure (19) . Several stud-
ies (20,21) suggested potential benefits of intermittent outpa-
tient therapy with dobutamine ; however, enthusiasm for this
form of therapy was diminished by a report (22) suggesting
increased mortality in patients receiving such therapy at high
doses. In contrast, a relatively small study (23) has demon-
strated beneficial effects of long-term continuous outpatient
therapy in patients with end-stage disease. The phosphodi-
esterase inhibitor amrinone can also provide hemodynami ..
improvements in patients with acute heart failure (24) ;
however, its cardiotortic 'effects might be limited by dimin-
ished levels of cyclic AMP in the failing myocardium (25) .
Because the adrenerpic agonists enhance intracellular levels
of cyclic AMP and phosphodiesterase inhibitors inhibit
degradation of the second messenger, the use of an adren-
ergic agonist and a phosphodiesterase inhibitor could theo-
retically be additive (26). In fact, several studies have shown
the benefits of combined therapy especially as transition
therapy in awaiting heart transplantation (27,28) .
Class II: Inotropic Agents Affecting
Sarcoletnmal Ion Pumps and Channels
A second group of inotropic agents are those that aug-
ment cardiac contractility by affecting the activity of selec-
tive ion pumps and channels within the sarcolemma and in so
doing altering intracellular calcium homeostasis . The proto-
type of this group of agents is digoxin . It is now well
Figure 1. Biochemical pathways im-
portant in regulation of cardiac contrac-
tility . AC = adenylyl cyclase; ATP =
adenosine triphosphate ; c.'ri _ cyclic
adenosine monophosphate ; DG = dia-
cyiglycerol; DR = delayed rectifier; G =
guanine nucleotide-binding regulatory
proteins that may stimulate (aG,) or
inhibit (&G;) adenylyl cyclase ; I = in-
ositol ; IP = inositol phosphate ; 1P2
_
inositol diphosphate ; IP3 = inositol
triphosphate; PDE = phosphodiester-
ase; PHLB = plwspholamban ; PI =
phosphotidylinositel; PIP = phosphoti-
dylinositol 4 phosphate ; PIP2 = phos-
photidylinositol 4 .5 . biphosphate ;
PKA = protein kinase A
; PKC = pro-
tein kinase C ; PLC =- phospholipase C ;
R = sarcolemmal receptor; It, = inhibi-
tory re :y°rtor ; R, = stimulatory recep-
tor; SR = sarcoplasmic reticulum; Tn =
tropenin .
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recognized that digoxin inhibits the sarcolemmal sodium-
potassium
adenosine triphosphatase resulting in increased
levels of intracellular sodium (29) (Fig
. 1) . This sodium is
then
exchanged for calcium by the sodium-calcium ex-
changer resulting in enhanced intracellular calcium levels,
enhanced release of calcium from intracellular stores and
increased cardiac contractility .
Although digoxin has been administered to patients with
congestive heart failure for more than 200 years, its use has
remained controversial (30,31) . However, several recent
multicenter clinical trials (15,32) demonstrate that digoxin
improves the ejection fraction, decreases the incidence of
worsening heart failure and improves exercise tolerance (15)
in patients with chronic congestive heirt failure receiving
concomitant therapy with a diuretic agent . The recent
RADIANCE trial (33) provided even more compelling evi-
dence of the beneficial effects of digoxin. When digoxin was
withdrawn frem patients who were already receiving an
angiotensin-converting enzyme inhibitor, there was a much
greater need for cointervention in those patients not °eceiv-
ing digoxin. However, the clinical use of digoxin is limited
by a narrow therapeutic index (34) and the long-term effects
of digoxin on survival remain undefined.
Class III: Agents That Modulate Intracellular
Calcium Mechanisms
A third group of inotropic agents augment cardiac con-
tractility by affecting intracellular calcium homeostasis
through increased release of calcium from the intracellular
stores in the sarcoplasmic reticulum (35) or by activation of
the phosphoinositide cascade (36,37) (Fig . 1) . Alternatively,
this group of agents can increase the sensitivity of the
contractile proteins to calcium particularly at the site of
troponin C and in so doing increase the contractile response
to any given level of intracellular calcium (38) . No agents are
currently under clinical investigation that act solely by one
of these two pathways . However, it is "1kely that new
investigational agents will be developed that utilize these
pathways .
Class IV: Inotropic Agents Having Multiple
Mechanisms of Action
A fourth group of inotropic agents are those drugs that
augment cardiac contractility by utilizing two or more bio-
chemical pathways. Two prototypes of this group are cur-
rently undergoing clinical investigation : pimobendan and
vesnarinone . Pimobendan is a benzimidazole-pyridazinone
derivative that is thought to augment cardiac contractility by
1) increasing the affinity of the regulatory site on troponin C
for calcium (39), and 2) having a modest inhibitory effect on
phosphodiesterase 111 (40) . However, in contrast to tradi-
tional phosphodiesterase inhibitor : , pimobendan prolongs
the action potential (41), suggesting the presence of other
FELDMAN
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ancillary effects
. Results from recent clinical trials (42)
suggest that pimobendan can increase exercise duratic .,
peak oxygen uptake and quality of life in patients with
chronic congestive heart failure already receiving standard
therapy including a vasodilator . Interestingly, these benefi-
cial effects were noted in patients receiving 5 mg/day but not
10 mg/day .
OPC-8212 or vesnarinone is a quinolinone derivative
that has unique mechanisms of action . In model systems,
vesnarinone decreased the outward and inward rectifying
potassium current (43); in fact, electrophysiologically it
closely resembled a class III antiarrhythmic agent (44) .
Vesnarinone also increased intracellular sodium as a result
of prolonged opening of sodium chunnels (45) . And, vesnari-
none increased the inward calcium current largely as a result
of modest inhibition of phosphodiesterase (46,47) . In marked
contrast to agents that increase intracellular cyclic AMP,
vesnarinone slows heart rate, prolongs the action potential
and suppresses the delayed outward potassium current (43) .
In a randomized placebo-controlled trial (48), vesnarinone
improved both quality of life and the combined end point of
mortality and major cardiovascular morbidity in patients
with symptomatic congestive heart failure . In addition, a
recent multicenter randomized placebo-controlled clinical
trial (49) demonstrated a substantial decrease in the risk of
worsening heart failure or death as well as a decrease in the
risk of all-cause mortality alone in patients receiving vesnari-
none when compared with those receiving placebo. These
beneficial effects were associated with a significant improve-
ment in quality of life ; the major risk associated with the use
of vesnarinone was reversible neutropenia, which occurred
in 2.5% of patients .
Benefits of a Classification System
Classification of the inotropic agents can provide intuitive
understanding of the potential benefits and limitations of
these agents. For example, inotropic agents that increase
intracellular cyclic AMP may improve hemodynamics
through ancillary vasodilator effects yet have the disadvan-
tage that they may increase heart rate and have the potential
to be either arrhythmogenic or cardiotoxic . In contrast,
agents that affect ion channels may slow heart rate and
therefore be cardioprotective . However, these agents may
also have vasodilator properties (l1). Finally, inotropic
agents with multiple mechanisms of action may combine
vasodilator, negative chronotropic and antiarrhythmic prop-
erties. Furthermore, it will be important to identify the
effects of these agents on both coronary hemodynamics and
myocardial energetics .
Although a classification system can help in understand-
ing the usefulness of inotropic agents, factors outside the
classification system mv.y also play a role in determining the
efficacy and use of any given agent . Recent evidence sug-
gests that the beneficial effects of many inotropic agents are
predicated on the dose of the drug. In studies using low
1226
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doses of the phosphodiesteraae inhibitor tnoximone, there
were trends toward increased exercise duration and de-
creased mortality when results were compared with those
achieved with placebo (50). In contrast, higher doses were
not associated with improvements in exercise tolerance and
there was a significant trend toward increased mortality .
Similar dose related effects have been seen in studies using
other investigational inotropic agents (17,49) . However, it is
also possible that the beneficial effects of some inotropic
agents are the result of ancillary properties, including anti-
arrhythatic or anticytokine activity, that are not associated
with their augmentation of cardiac contractility . Recent
studies (51) suggest that the vasodilator flosequinan also has
inotropic properties; however, the mechanisms responsible
for these inotropic properties have not yet been defined .
Therefore, it will be important to include in a classification
system pharmacologic agents with ancillary positive inotro-
pic effects .
Conclusions
Recent investigations suggest that some inotropic agents
may be beneficial in the short-term management of patients
with congestive failure as well as in the long-term therapy of
patients with chronic myocardial disease . Because many of
the new investigational inotropic agents differ in their mech-
anisms of action from the more traditional adrenergic ago-
nists and phosphodiesterase inhibitors, it has become in-
creasingly important to classify these agents according to
their mechanisms of action rather than to view them in the
generic sense . This attempt to classify the inotropic agents
according to their mechanisms of action is analogous to the
classification of antiarrhythmic agents first proposed by
Vaughan Williams >20 years ago (52) . As with the amine
rhythmic agents, the classification system must remain flex-
ible and not rigid. Furthermore, such a classification does
not suggest that some groups of inotropic agents are neces-
sarily more effective than others, but it provides a frame-
work for better understanding of the increasing number of
new in otropic agents . The potential benefits of each individ-
ual agent within the four groups of inotropic drugs must be
thoroughly assessed by scientific analysis as well as by the
individual practitioner.
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